Genentech, the South San Francisco-based subsidiary of Roche, has started construction on a new biomanufacturing facility in Holly Springs, North Carolina. The $700 million project marks the company’s first manufacturing investment on the U.S. East Coast and is expected to support the production of future metabolic treatments, including obesity therapies.

The site, covering roughly 65,000 square meters, is part of a broader $50 billion investment by Roche in U.S.-based manufacturing, infrastructure and R&D. Construction is scheduled for completion by 2029. The 400,000-square-meter campus includes additional space for future expansion.

Once operational, the facility is expected to create more than 1,900 jobs. Genentech cited the region’s skilled workforce, research institutions and concentration of life science companies as key reasons for selecting Holly Springs.
“This $700 million project is an integral part of our broader $50 billion commitment to further expand our already significant presence in the United States,” said Roche Group CEO Thomas Schinecker. “I am excited about the impact this facility will have on delivering life-changing medicines to patients in the U.S. and around the world.”

The site will incorporate advanced biomanufacturing technologies, including automation and digital infrastructure, aimed at increasing production efficiency and flexibility. Roche said the facility will strengthen its global supply chain and complement existing sites in Europe and Switzerland.

Roche has maintained a presence in the United States for more than a century. Through Genentech and other affiliates, it has continued to expand its R&D and manufacturing footprint in the country, which remains a key market for the company’s pharmaceutical and diagnostic products.

U.S. Healthcare Homepage